Back

Learner’s Digest International (TM)

  • Breast Neoplasms
  • Estrogens
  • Venous Thromboembolism

CDK4/6 Inhibitor Therapy in Early-stage HR+/HER2+ Breast Cancer

The goal of this program is to improve management of early breast cancer (BC) with cyclin-dependent kinase (CDK) inhibitors. After hearing and assimilating this program, the clinician will be better able to: 1. Mitigate the risk for venous thromboembolism associated with abemaciclib in patients with high-risk, node-positive, estrogen receptor (ER)-positive, human epidermal growth factor receptor 2 (HER2)-negative BC. 2. Analyze the clinical benefits of adjuvant ribociclib for patients with high-risk, ER-positive, HER2-negative BC.

Credit & MOC Details

Credit information is provided by the course provider. We recommend confirming credit eligibility with the provider or your licensing board before starting the activity.

Credit types

AMA PRA Category 1 Credit™Up to 1 credit

MOC types

ABIM — Medical KnowledgeUp to 1 point

FDA REMS

No

Qualifies for MIPS

No

Pricing

Membership pricing — $1,095 / year

This provider prices CME through membership. Individual courses may also be sold separately.

See plans on audio-digest.org

Listed by the provider

  • Enduring / On-demand
  • Credit · Up to 1 credit
  • MOC · Up to 1 point
  • Membership pricing
  • Released
    Sep 1, 2026
  • Last day to claim credit
    Sep 22, 2027 11 months left